PM Society and CIM launch new leadership programme for pharma marketers
June 13, 2025Sales and Marketing CIM Fellowship, Chartered Institute of Marketing (CIM), Corporate, Marketing Excellence Industry Group, PM Society Awards, Pharmaceutical Marketing (PM) Society, Pharmacy, partnership
The Pharmaceutical Marketing (PM) Society has partnered with the Chartered Institute of Marketing (CIM) to launch the PMS & CIM …
Digital platform for hypertension management launches in Europe
June 13, 2025Business Services, Technical Consultancy Chronic Diseases, HealthTech, Newel Health, digital platform, high blood pressure, hypertension management, hypertension therapy
Newel Health, a European healthtech company specialising in digital medical devices, has announced that Amicomed, its digital platform for hypertension …
PL BioScience appoints Oliver Dick as chief technology officer
June 12, 2025Clinical trials supplies & documentation logistics, Manufacturing and Production, Research and Development Corporate, Devices, Human Platelet Lysate, PL Bioscience, animal-free cell culture, life sciences
PL BioScience, a German life sciences company specialising in the production and development of human platelet lysate (HPL) for cell …
Ascend granted certification for quality control testing at Munich facility
June 12, 2025Contract Manufacturing, Manufacturing Services, Manufacturing and Production Adeno-associated (AAV)-based gene therapy., Ascend Advanced Therapeutics, Devices, Pharmacy, adeno-associated gene therapy, contract development and manufacturing organisation, good manufacturing practice certification, manufacturing site
Ascend Advanced Therapies, a contract development and manufacturing organisation based in Maryland, US, has received good manufacturing practice (GMP) certification …
Chiesi partners with Key2Brain to develop therapies for rare neurodegenerative diseases
June 12, 2025Manufacturing and Production, Mergers and Acquisitions, Research and Development Chiesi Group, Key2Brain, Neurology, Rare Diseases, lysosomal storage disorders, neurodegenerative disease, partnership, ultra-rare disease
Italian biopharma, Chiesi Group, and Key2Brain, a Swedish biotech, have agreed to advance the development of two blood-brain barrier (BBB)-crossing …
Treatment for serious eye disease approved in Scotland
June 12, 2025Market Access, Marketing Services, Research and Development, Sales and Marketing LYTENAVA, Opthalmology, Scottish Medicines Consortium, clinical programme, european union, eye disease, market approval, strategic partnership, united kingdom, wet age-related macular degeneration
Outlook Therapeutics has announced the Scottish Medicines Consortium (SMC) approval of Lytenava (bevacizumab gamma) for the treatment of wet age-related …
PEPperPRINT launches new peptide microarray platform on 15th anniversary
June 11, 2025Biotech/start-up, Research and Development, Sales and Marketing Devices, PEPperPRINT, biotech research, peptide microarray platform
German biotech PEPperPRINT has marked its 15th anniversary with the launch of a new peptide microarray platform, combinatorial laser-induced forward …
Meteor Biotech opens site at UCLA to support biotech research
June 11, 2025Biotech/start-up, Research and Development, Sales and Marketing Devices, Immunology, Meteor Biotech, Oncology, Pharmacy, University of California Los Angeles, cell sorting technology, clinical trials, research facility
South Korean spatial omics specialist, Meteor Biotech, has announced the opening of its first international office at the California NanoSystems …
BioDuro and Silicogenix collaborate to advance non-traditional drug development
June 11, 2025Manufacturing Services, Manufacturing and Production, Research and Development BioDuro, Oncology, Pharmacy, Silicogenix, contract research, contract research development and manufacturing organisation (CRDMO), drug development
BioDuro, a contract research, development and manufacturing organisation, has announced a strategic partnership with small molecule design specialist Silicogenix (SGX) …
Dupixent improves symptoms in patients with skin of colour, study shows
June 11, 2025Advocacy Development, Medical Education, Research and Development Dermatology, Dupixent, Regeneron, Sanofi, atopic dermatitis, dermatology, underserved populations
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at the Revolutionizing Atopic Dermatitis Conference, …
Lubrizol announces an important milestone for its novelpatented excipient, Apisolex™ polymer
June 10, 2025Research and Development Apisolex polymer, Good Manufacturing Practices (GMP) guidelines, Lubrizol, Pharmacy, clinical trial
June 10, 2025 – Lubrizol announces that an Apisolex™ polymer excipient-enabled drugformulation is in Phase 1 clinical trials. Introduced to …
Takeda presents positive results from trial of chronic kidney disease treatment
June 10, 2025Research and Development European Renal Association, Immunology, Nephrology, Takeda, autoimmune disease, immunoglobulin A nephropathy (IgAN), kidney disease
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A …
ANGLE’s Parsortix system used in new cancer biology research
June 10, 2025Medical Communications, Research and Development Angle, Oncology, Parsortix system, R&D, biotech, oncology, scientific journals
ANGLE has announced three new peer-reviewed publications demonstrating the use of its Parsortix circulating tumour cell (CTC) harvesting system in …
Hansa Biopharma to host investor event on Guillain-Barré Syndrome to accelerate research
June 10, 2025Conferencing, Events & Incentives, Interactive Conferences, Medical Communications, Research and Development, Sales and Marketing Guillain-Barré syndrome, Hansa Biopharma, Immunology, Neurology, investor event
Hansa Biopharma (Hansa) will host a virtual investor event on Guillain-Barré syndrome (GBS) on 16 June 2025. The webcast aims …
Vertex presents promising new data from cystic fibrosis trials
June 9, 2025Medical Communications, Research and Development European Cystic Fibrosis Conference, Rare Diseases, Vertex, clinical trial, cystic fibrosis
Vertex Pharmaceuticals has presented new data showing the clinical and quality-of-life benefits of its cystic fibrosis (CF) therapies, particularly Alyftrek …
Corcept reports survival benefit in ALS trial of dazucorilant despite missing primary endpoint
June 9, 2025Research and Development Corcept Therapeutics, European Network to Cure ALS (ENCALS), Neurology, amyotrophic lateral sclerosis, clinical trial
Corcept Therapeutics has announced results from its phase 2 DAZALS study investigating dazucorilant in patients with amyotrophic lateral sclerosis (ALS), …
Study into treatment for rare condition in premature infants launches globally
June 9, 2025Research and Development Chiesi Farmaceutici, Elgan Pharma, Gastrointestinal tract, Paediatrics, clinical trial, intestinal malabsorption, premature infant health
Elgan Pharma, specialising in neonatology, and Italy-based biopharma, Chiesi Farmaceutici, have announced the dosing of the first participating infants in …
The unbearable lightness of creativity
June 9, 2025Medical Communications, Sales and Marketing 21GRAMS, Atomic Matter, Corporate, HAVAS LYNX, London UK, PM Society Awards, Pharmacy, pharma healthcare communications, pharma marketing
21GRAMS and Havas Lynx lead the charge at the PM Society Awards for pharma marketing and healthcare communications Commenting on …
Trial into rare genetic disease Werner syndrome reports promising results
June 6, 2025Research and Development Chiba University, Niagen Bioscience, Rare Diseases, Werner Syndrome, clinical trial, rare genetic disease
Researchers at Chiba University, Japan, alongside Niagen Bioscience, have reported successful results from the world’s first trial of nicotinamide riboside …
Osivax reaches key milestone in phase 2a trial for broad-spectrum flu vaccine
June 6, 2025Research and Development Ghent University Hospital, Osivax, Vaccine, Virology, clinical trial, influenza a
Osivax has announced the completion of patient visits in its phase 2a trial evaluating a booster dose of OVX836, a …
Latest content
FibroFind appoints Lee Borthwick as CEO
